Infection of Peruvian Aotus nancymai Monkeys with Different Strains of Plasmodium falciparum, P. vivax, and P. malariae

We, Collins; Jc, Skinner; Pappaioanou, Marguerite; Broderson,; Ns, Ma; Filipski,; Ps, Stanfill; Rogers, Linda

doi:10.2307/3282044

Cited by 21 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Aotus monkeys are usually less susceptible to infection via sporozoite inoculation, many strains of this parasite have been adapted to develop in Aotus monkeys. [20][21][22][23][24][25][26][27][28][29][30] Further studies to assess the efficacy of yP 2 P 30 Pv200 19 and other blood-stage candidate vaccines may better be conducted in Aotus monkeys using a strain of P. vivax shown to induce predictably high-density parasitemia in intact animals. Attempts will be made to establish such a model using strains of the parasite already adapted to monkeys.…”

Section: Discussionmentioning

confidence: 99%

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.

Collins

Kaslow²,

Sullivan³

et al. 1999

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Saimiri boliviensis monkeys were immunized with the yeast-expressed recombinant protein yP 2 P 30 Pv200 19 . The antigen consisted of the C-terminus (amino acid Asn 1622 -Ser 1729 ) of the merozoite surface protein 1 of the Plasmodium vivax Salvador I strain. Two universal T helper cell epitopes (P 2 and P 30 ) of tetanus toxin and six histidine residues for purification purposes were attached to the N-and C-termini, respectively. Four groups of five monkeys were given three immunizations at four-week intervals with either 250 g of yP 2 P 30 Pv200 19 formulated with nonionic block copolymer P1005, 250 g of antigen adsorbed to alum, 250 g of antigen in phosphate-buffered saline (PBS), or PBS alone. Five weeks after the last immunization, each animal was inoculated with 100,000 parasitized erythrocytes of the Salvador I strain of P. vivax. Animals were splenectomized one week after challenge to increase parasite densities; after seven weeks of infection, animals were treated. Eighteen weeks later, the animals were rechallenged with the homologous parasite. Following the first challenge, three monkeys immunized with the antigen with P1005 were protected; no animals were protected from rechallenge. One monkey immunized with yP 2 P 30 Pv200 19 with alum was protected; no protection was seen after rechallenge. Two monkeys immunized with antigen alone were protected; none were protected from rechallenge. One control animal had a low parasite count following primary infection; none were protected against rechallenge. Adverse reactions were only observed with animals receiving P1005. It is proposed that splenectomy of the monkeys prevented adequate assessment of the efficacy of this antigen. Identification of a monkey host that supports high density parasitemia without splenectomy appears needed before further testing of blood-stage vaccines against P. vivax.Procedures are being developed and evaluated for the testing of different synthetic peptide and recombinant protein vaccines in animals susceptible to infection with different species of Plasmodium. A model system has been developed for the testing of vaccines directed against the sporozoites of Plasmodium vivax using the Salvador I strain of the parasite and the nonhuman primate model of Saimiri boliviensis boliviensis. [1][2][3][4][5][6][7] In previous trials, immunized animals were challenged with 10,000 or more sporozoites dissected from the salivary glands of infected mosquitoes, and the animals were splenectomized one week after challenge to increase parasitemia. Infection rate was highly predictable, but prepatent periods varied markedly.Our present study was designed to determine if this model system could be used to test the efficacy of a recombinant vaccine directed against the merozoite surface protein (MSP-1 19 ) of P. vivax. To increase uniformity of parasitemia, all animals were challenged by the intravenous inoculation of parasitized erythrocytes. All animals were splenectomized seven or eight days after challenge. Included in the trial were ...

show abstract

Section: Discussionmentioning

confidence: 99%

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.

Collins

Kaslow²,

Sullivan³

et al. 1999

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…20,2007 PLASMODIUM MALARIAE: PARASITE AND DISEASE 587 monkeys was reported by Geiman and Siddiqui (49). Additional studies were made with different species of Aotus and Saimiri monkeys (23,28,32,33,34,36). In splenectomized Aotus monkeys, maximum parasite counts with P. malariae varied markedly, from 10 to 56,800/l.…”

Section: Infections In Chimpanzees and Monkeysmentioning

confidence: 99%

Plasmodium malariae : Parasite and Disease

2007

Self Cite

View full text Add to dashboard Cite

SUMMARY A review of the life history of Plasmodium malariae, the quartan malaria parasite of humans, is presented. Much of the information is based on data obtained from induced infections in humans who were given malaria therapy for the treatment of neurosyphilis between 1940 and 1963. Prepatent periods (i.e., the time until the first day of parasite detection) fever episodes, and maximum parasitemias as a result of infection with P. malariae were obtained and are presented. Experimental and known vectors of the parasite are also discussed. Splenectomized chimpanzees and New World monkeys are readily infected and serve as sources of parasites and antigens for diagnostic and molecular studies. South American monkeys are naturally infected with a parasite known as Plasmodium brasilianum. This parasite appears to be P. malariae that has adapted from humans to grow in monkeys, probably within the last 500 years. Infection with P. malariae is associated with the production of immune complexes in the kidneys and the associated nephrotic syndrome. The essential lesions are a thickening of the glomerular basement membrane and endocapillary cell proliferation. Studies of monkeys infected with P. malariae indicate the same pathology as that demonstrated in humans.

show abstract

“…The sequence includes a protective octapeptide 6 , 9 , two inverted amino acids in positions 8 and 9 (IN to NI replacement) and an S to V replacement in position 15 (shown in bold) 19 . Establishing, characterizing and evaluating the proliferative response of AnTMSA2 to the modified peptide and d ‐analogues will allow us to understand the contribution made by different amino‐acid residues toward specific T‐cell recognition, CD4 T‐cell induction and their role in immunogenic conversion, and finally to validate this system for assessing subunit vaccine candidates in the recommended experimental model, Aotus sp., for P. falciparum malaria 22 , 23 , 24 .…”

Section: Introductionmentioning

confidence: 99%

Herpesvirus saimiri immortalization of Aotus T lymphocytes specific for an immunogenically modified peptide of Plasmodium falciparum merozoite surface antigen 2

et al. 2005

View full text Add to dashboard Cite

SummaryThe Plasmodium merozoite surface antigen 2 (MSA2) is one of several candidates for a protective vaccine against malaria. Previous studies have shown that antibodies directed against the MSA2 variable region are not protective and that constant regions are non-immunogenic. However, modified peptides derived from constant regions can be rendered immunogenic and partially protective in Aotus monkeys. In this study, we reveal the establishment, using in vitro Herpesvirus samiri (HVS) infection, of an Aotus monkey T-cell line (AnTMSA2) specific for a modified immunogenic and partially protective peptide derived from a constant and highly conserved region of MSA2 (SKYSNTFINNAYNMSIRRSM). AnTMSA2 is a CD4 T lymphocyte expressing high levels of MHC class II molecules, CD58 and CD2, which are important for proliferation and growth. AnTMSA2 proliferates specifically in response to the modified monomeric MSA2 peptide sequence. It is also capable of specific antigen recognition after glycine-cysteine-polymerized sequence processing and presentation by autologous APC. Interestingly, AnTMSA2 presents cross-reactivity with D -peptide analogues in which residues in positions 8 and 9 were changed for N D I D residues. Therefore, at least for this particular sequence, polymerized D -peptides could be used for immunizing animals without losing the immunogenic epitope. AnTMSA2 presents a cytokine profile corresponding to a Th0-like pattern, which suggests that as a result of HVS immortalization AnTMSA2 is in transit from a Th2 to a Th1 pattern. Taken together our results suggest that Th2 T-cell induction and/or T-cell cross-reactivity generation by the modified peptide could be responsible for the immunogenic conversion observed in Aotus monkeys and that D -peptide analogues with longer half-lives could provide an alternative for inducing protective immunity.

show abstract

Infection of Peruvian Aotus nancymai Monkeys with Different Strains of Plasmodium falciparum, P. vivax, and P. malariae

Cited by 21 publications

References 0 publications

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.

Plasmodium malariae : Parasite and Disease

Herpesvirus saimiri immortalization of Aotus T lymphocytes specific for an immunogenically modified peptide of Plasmodium falciparum merozoite surface antigen 2

Contact Info

Product

Resources

About